Articles from ENDRA Life Sciences Inc.

ENDRA Life Sciences Inc. (NASDAQNDRA), an innovator of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that it has regained compliance with the minimum bid price requirement set forth by The Nasdaq Stock Market LLC (“Nasdaq”).

ENDRA Life Sciences Inc. (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three and nine months ended September 30, 2024 and provided a business update.

ENDRA Life Sciences Inc. (NASDAQNDRA), an innovator of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced the acceptance of a poster titled “Noninvasive assessment of steatotic liver disease in individuals with class 2 and class 3 obesity” for presentation at The Liver Meeting 2024, hosted by the American Association for the Study of Liver Disease (AASLD), taking place November 15-19 in San Diego.

ENDRA Life Sciences Inc. (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the European Patent Office has issued to ENDRA a new patent EP4247282 (the ‘282 patent) titled “Method and System for Monitoring Tissue Temperature.”

ENDRA Life Sciences Inc. (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the activation of a post market clinical study and first patient scanned with the TAEUS liver system at LMU University Hospital in Munich, one of the leading medical research centers in Europe.

ENDRA Life Sciences Inc. (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that on August 27, 2024, the Company was notified by The Nasdaq Stock Market LLC (“Nasdaq”) that the Nasdaq Hearings Panel (the “Panel”) has granted the Company’s request for an extension through November 20, 2024, to evidence compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market.

ENDRA Life Sciences Inc. (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), reports financial results for the three and six months ended June 30, 2024, as filed in a Form 10-Q on August 14, 2024, and provides the following business update:

ENDRA Life Sciences Inc. (“ENDRA”) (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that it will implement a 1-for-50 reverse stock split of the issued shares of its common stock (the “Reverse Stock Split”), effective at 12:01 a.m. Eastern time on August 20, 2024. The Company’s common stock is expected to begin trading on a split-adjusted basis when the market opens on Tuesday, August 20, 2024, and will continue to trade on The Nasdaq Capital Market under the symbol “NDRA.” The new CUSIP number for the common stock will be 29273B 401.

ENDRA Life Sciences Inc. (“ENDRA”) (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that it will host a conference call and webcast beginning at 4:30 p.m. Eastern time on August 22, 2024, to discuss quarterly results, provide an update on recent corporate developments and answer questions. This call was previously scheduled for August 14, 2024.

ENDRA Life Sciences Inc. (“ENDRA”) (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced its Board of Directors has appointed Alexander Tokman as acting Chief Executive Officer to replace Francois Michelon, who stepped down from his role as Chief Executive Officer and as a member of the Board of Directors to pursue other endeavors. The Company also announced the addition to its senior management team of Ziad Rouag as Head of Regulatory and Clinical Affairs and Richard Jacroux as Chief Financial Officer.

ENDRA Life Sciences Inc. (ENDRA) (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that the company will report financial results for the three and six months ended June 30, 2024 on Wednesday, August 14, 2024 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at 4:30 p.m. Eastern time to discuss the results, provide an update on recent corporate developments and answer questions.

ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announced today that it has priced a public offering with gross proceeds to the Company expected to be approximately $8.0 million, before deducting placement agent fees and other estimated expenses payable by the Company. The offering is a best-efforts offering, with no minimum amount of securities required to be sold.

ENDRA Life Sciences Inc. (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announced that it has completed what it considers to be a highly informative pre-submission meeting with the U.S. Food and Drug Administration (FDA) related to the clinical trial design of the TAEUS liver device in support of its U.S. De Novo filing.

ENDRA Life Sciences Inc. (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three months ended March 31, 2024 and provided a business update.

ENDRA Life Sciences Inc. (ENDRA) (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that the company will report financial results for the three months ended March 31, 2024 on Tuesday, May 14, 2024 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at 4:30 p.m. Eastern time to discuss the results, provide an update on recent corporate developments and answer questions.

ENDRA Life Sciences Inc. (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the issuance of five new patents, including three in Europe and two in China. ENDRA’s intellectual property (IP) portfolio now includes 80 issued patents worldwide, providing protection for the TAEUS system with its novel thermoacoustic technology.

ENDRA Life Sciences Inc. (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reports financial results for the three months and year ended December 31, 2023 and provides a business update.

ENDRA Life Sciences Inc. (ENDRA) (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that the company will report financial results for the three months and year ended December 31, 2023 on Thursday, March 28, 2024 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at 4:30 p.m. Eastern time to discuss the results, provide an update on recent corporate developments and answer questions.

ENDRA Life Sciences Inc. (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that it has installed a TAEUS liver system at King's College Hospital NHS Foundation Trust (KCH) in London, one of the leading centers of excellence in the United Kingdom's National Health Service (NHS).

ENDRA Life Sciences Inc. (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), welcomes the adoption of the ICD-10 K76.0 code for the diagnosis of Non-Alcoholic Fatty Liver Disease (NAFLD). This pivotal update supports recent important advancements in the field of liver disease to underscore the increasing recognition of NAFLD's impact on global health by insurers and healthcare providers alike. ENDRA’s TAEUS system has received a CE mark in the European Union and is the subject of a De Novo request that is pending before the U.S. Food and Drug Administration (FDA).

ENDRA Life Sciences Inc. (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the issuance of three new patents, including one in the U.S., one in China and one in Europe. ENDRA’s intellectual property portfolio now includes 74 issued patents worldwide providing protection for the TAEUS system with its novel thermoacoustic technology.

ENDRA Life Sciences Inc. (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the United States Patent and Trademark Office has issued to ENDRA a new patent, U.S. Patent No. 11828727 (the ‘727 patent) titled “Thermoacoustic Probe.”

ENDRA Life Sciences Inc. (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that management will be participating in The Benchmark Company’s 12th Annual Discovery One-on-One Investor Conference being held Thursday, December 7, 2023 at the New York Athletic Club in New York City. Management will be holding one-on-one meetings with investors.

ENDRA Life Sciences Inc. (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reports financial results for the three and nine months ended September 30, 2023 and provides a business update. Highlights from the third quarter of 2023 and recent weeks include:

ENDRA Life Sciences Inc. (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the issuance of three new patents, including one in the U.S. and two in China. ENDRA’s intellectual property (IP) portfolio now includes 70 issued patents worldwide, enhancing the IP protection for the novel TAEUS® system.

ENDRA Life Sciences Inc. (ENDRA) (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that the company will report financial results for the three and nine months ended September 30, 2023 on Tuesday, November 14, 2023 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at 4:30 p.m. Eastern time to discuss the results, provide an update on recent corporate developments and answer questions.

ENDRA Life Sciences Inc. (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced it will host an offsite panel discussion with multidisciplinary experts during the American Association for the Study of Liver Diseases (AASLD) annual meeting, The Liver Meeting, taking place November 10-14, 2023, in Boston. The panel will feature three key opinion leaders (KOLs) in the fields of hepatology, endocrinology and radiology sharing their unique perspectives on managing Metabolic-Associated Steatotic Liver Disease (MASLD).

ENDRA Life Sciences Inc. (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced the acceptance of a clinical abstract titled “Thermoacoustic assessment of fatty liver disease - a clinical feasibility study” for presentation at the Steatotic Liver Disease Summit™ 2023 hosted by the European Association for the Study of the Liver (EASL), taking place September 21-23 in Prague, Czechoslovakia.

ENDRA Life Sciences Inc. (NASDAQNDRA), a pioneer of imaging technologies and Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the Company's De Novo request for the TAEUS liver system has advanced to substantive review with the U.S. Food and Drug Administration (FDA). The TAEUS system is ENDRA’s proprietary device that is intended to offer clinicians a tool for the non-invasive assessment of fatty liver tissue, as an aid in the management of patients with Non-Alcoholic Fatty Liver Disease (NAFLD).

ENDRA Life Sciences Inc. (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the issuance of three new patents, one in the U.S. and two in Europe. ENDRA’s intellectual property portfolio now includes 67 issued patents worldwide, providing protection for the TAEUS® system with its novel hybrid ultrasound and thermoacoustic imaging technology.

ENDRA Life Sciences Inc. (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three and six months ended June 30, 2023 and provided a business update. Highlights from the second quarter of 2023 and recent weeks include:

ENDRA Life Sciences Inc. (NASDAQNDRA), a pioneer of imaging technologies and Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the submission of a De Novo request to the U.S. Food and Drug Administration (FDA) for the TAEUS system. The TAEUS system is ENDRA’s proprietary device that is intended to offer clinicians a tool for the non-invasive assessment of fatty liver tissue, as an aid in the management of patients with Non-Alcoholic Fatty Liver Disease (NAFLD).

ENDRA Life Sciences Inc. (ENDRA) (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that the company will report financial results for the three and six months ended June 30, 2023 on Monday, August 14, 2023 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at 4:30 p.m. Eastern time to discuss the results, provide an update on recent corporate developments and answer questions.

ENDRA Life Sciences Inc. (NASDAQNDRA) (the “Company”), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced its 2023 Annual Meeting of Stockholders (the “Annual Meeting”), which was scheduled to be held this morning, was convened and adjourned, without any business being conducted, due to the lack of the required quorum.

ENDRA Life Sciences Inc. (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced the acceptance of a poster titled “Thermoacoustic assessment of fatty liver disease - an early clinical feasibility study” for presentation at the International Liver Congress™ 2023 hosted by the European Association for the Study of the Liver (EASL), taking place June 21-24 in Vienna, Austria.

ENDRA Life Sciences Inc. (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three months ended March 31, 2023 and provided a business update. Highlights include:

ENDRA Life Sciences Inc. (ENDRA) (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that the company will report financial results for the three months ended March 31, 2023 on Monday, May 15, 2023 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at 4:30 p.m. Eastern time to discuss the results, provide an update on recent corporate developments and answer questions.

ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announced today the closing of its previously announced underwritten public offering of 4,312,500 shares of its common stock and warrants to purchase 2,156,250 shares of its common stock, which included the exercise in full by the underwriter of its option to purchase 562,500 additional shares of ENDRA’s common stock and additional warrants to purchase 281,250 shares of common stock. The warrants were sold at the rate of one warrant for every two shares of common stock and are exercisable at a price per share of $1.40. The public offering price for each set of two shares of common stock and accompanying warrant to purchase one share of common stock was $2.41 per set of securities, yielding an effective price of $1.20 per share and $0.01 per warrant, for net proceeds of approximately $4.5 million after deducting the estimated underwriting discounts and commissions and estimated offering expenses.

ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announced today that it has priced an underwritten public offering of 3,750,000 shares of its common stock and warrants to purchase 1,875,000 shares of its common stock. The warrants are being sold at the rate of one warrant for every two shares of common stock and will be exercisable at a price per share of $1.40. The public offering price for each set of two shares of common stock and accompanying warrant to purchase one share of common stock is $2.41 per set of securities, yielding an effective price of $1.20 per share and $0.01 per warrant, for net proceeds of approximately $3.9 million after deducting the estimated underwriting discounts and commissions and estimated offering expenses.

ENDRA Life Sciences Inc. (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three months and year ended December 31, 2022, and provided a business update. Highlights include:

ENDRA Life Sciences Inc. (ENDRA) (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that the company will report financial results for the three months and year ended December 31, 2022 on Tuesday, March 14, 2023 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at 4:30 p.m. Eastern time to discuss the results, provide an update on recent corporate developments and answer questions.

ENDRA Life Sciences Inc. (NASDAQNDRA) (the “Company”), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announced today that it will be effecting a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20. The reverse stock split will reduce the number of shares of the Company’s common stock outstanding from 63,174,455 shares to approximately 3,158,723 shares, subject to adjustment for the rounding up of fractional shares. The Company is confirming with the Nasdaq Stock Market the effective date of the reverse stock split, when ENDRA’s common stock will begin trading on a split-adjusted basis under the existing trading symbol “NDRA” and a new CUSIP number.

ENDRA Life Sciences Inc. (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three and nine months ended September 30, 2022, and provided a business update. Highlights of the third quarter of 2022 and recent weeks include:

ENDRA Life Sciences Inc. (ENDRA) (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that the company will report financial results for the third quarter of 2022 on Monday, November 14, 2022 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at 4:30 p.m. Eastern time to discuss the results, provide an update on recent corporate developments and answer questions.

ENDRA Life Sciences Inc. (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the United States Patent and Trademark Office has issued two new ENDRA patents, U.S. Patent No. 11456518 (the ‘518 patent) titled “Method for Manufacturing a Radio Frequency Applicator” and U.S. Patent No. 11478153 (the ‘153 patent) titled “System for Monitoring Tissue Temperature.”

ENDRA Life Sciences Inc. (NASDAQNDRA), a pioneer of imaging technologies and Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that management will present a company overview at the H.C. Wainwright 6th Annual NASH Investor Conference being held October 17, 2022 in a virtual format, and will also be holding one-on-one virtual meetings. To request a meeting, please contact H.C. Wainwright or Yvonne Briggs of LHA at ybriggs@lhai.com.

ENDRA Life Sciences Inc. (NASDAQNDRA), a pioneer of imaging technologies and Thermo Acoustic Enhanced UltraSound (TAEUS®), announces an update to its plan to submit a De Novo request for the TAEUS system to the U.S. Food and Drug Administration (FDA).

ENDRA Life Sciences Inc. (NASDAQNDRA), a pioneer of imaging technologies and Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that management will present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference being held September 12-14, 2022 in a virtual format and in-person in New York City and will be holding one-on-one meetings. A webcast of the presentation will be available on-demand beginning September 12, 2022 at 7:00 a.m. Eastern time on the Investors section of ENDRA’s website.

ENDRA Life Sciences Inc. (NASDAQNDRA), a pioneer of imaging technologies and Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the European Patent Office has issued European Patent No. 3730041 (the ‘041 patent) to ENDRA titled “System for Estimating Fractional Fat Content of an Object.” The ‘041 patent protects ENDRA's TAEUS system for the calculation of fat concentration in the human body with multiple thermoacoustic measurements. The ‘041 patent is related to U.S. patent 9980677B1 and Chinese patent ZL201880050042.2.

ENDRA Life Sciences Inc. (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three and six months ended June 30, 2022, and provided a business update. Highlights of the second quarter of 2022 and recent weeks include:

ENDRA Life Sciences Inc. (ENDRA) (NASDAQNDRA), a pioneer of enhanced ultrasound technologies, today announced that the company will report financial results for the second quarter of 2022 on Monday, August 15, 2022 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at 4:30 p.m. Eastern time to discuss the results, provide an update on recent corporate developments and answer questions.

ENDRA Life Sciences Inc. (NASDAQNDRA), a pioneer of imaging technologies and Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the United States Patent & Trademark Office has issued three new patents to ENDRA including U.S. Patent No. 11379343 (the ‘343 patent), U.S. Patent No. 11392479 (the ‘479 patent) and U.S. Patent No. 11405470 (the ‘470 patent). All three patents are titled “Methods and Systems for Exchange of Equipment Performance Data.”

ENDRA Life Sciences Inc. (NASDAQNDRA), a pioneer of enhanced ultrasound technologies, today announced that management will be participating in the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference being held August 15-16, 2022. Management will host one-on-one virtual meetings with investors. To request a meeting, please contact Needham or Yvonne Briggs of LHA at ybriggs@lhai.com.

ENDRA Life Sciences Inc. (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the United States Patent and Trademark Office has issued a new ENDRA patent, U.S. Patent No. 11369272 (the ‘272 patent) titled “Broadband Applicator for Thermoacoustic Signal Generation.”

ENDRA Life Sciences Inc. (NASDAQNDRA), a pioneer of enhanced ultrasound technologies, today announced that management will be participating in the JMP Securities Life Sciences Conference being held June 15-16, 2022 in New York City. Management will present a company overview on Wednesday, June 15th at 2:30 p.m. Eastern time and will host one-on-one meetings with investors. To request a meeting, please contact JMP Securities or Yvonne Briggs of LHA at ybriggs@lhai.com.

ENDRA Life Sciences Inc. (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the United States Patent & Trademark Office has issued a new patent to ENDRA, U.S. Patent No. 11337676 (the ‘676 patent) titled “Acoustically Compatible Radio-frequency Applicator Method and System.” The ‘676 patent protects ENDRA's method and system for optimizing the delivery of radiofrequency (RF) energy to tissue using TAEUS, and serves as the parent patent for applications being prosecuted in China and in Europe.

ENDRA Life Sciences Inc. (NASDAQNDRA), a pioneer of enhanced ultrasound technologies, announces that management will present a company overview at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 in Miami Beach and will be holding virtual one-on-one meetings. A webcast of the presentation will be available on-demand beginning May 24, 2022 at 7:00 a.m. Eastern time on the Investors section of ENDRA’s website.

ENDRA Life Sciences Inc. (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three months ended March 31, 2022, and provided a business update. Highlights of the first quarter of 2022 and recent weeks include:

ENDRA Life Sciences Inc. (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the issuance of four new patents, two in the U.S. and two in China. ENDRA’s intellectual property portfolio now includes 90 assets, including 46 issued patents worldwide providing protection for the TAEUS system with its novel hybrid ultrasound and thermoacoustic imaging technology. One of the newly issued U.S. patents, which protects the ability to transfer data without an internet connection, expands potential licensing opportunities for the company.

ENDRA Life Sciences Inc. (ENDRA) (NASDAQNDRA), a pioneer of enhanced ultrasound technologies, today announced that the company will report financial results for the first quarter of 2022 on Thursday, May 12, 2022 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at 4:30 p.m. Eastern time to discuss the results, provide an update on recent corporate developments and answer questions.

ENDRA Life Sciences Inc. (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the Company has raised $8.7 million in gross proceeds year-to-date from the sale of common stock through its at-the-market (ATM) equity facility. Pursuant to its ATM equity offering sales agreement with Ascendiant Capital Markets LLC, the Company sold approximately 20.6 million shares of common stock at an average price of $0.42 per share.

ENDRA Life Sciences Inc. (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces receipt of Medical Device Quality Management System ISO 13485:2016 and EN ISO 13485:2016 recertification, under Certificate Number MD 697226 from the British Standards Institution (BSI). This recertification affirms the company's Quality Management System (QMS) meets all current regulatory requirements specific to the medical device industry. The U.S. Food and Drug Administration (FDA) has proposed adopting the ISO 13485:2016 standard, in an effort to harmonize the FDA Quality System Regulation, 21 CFR 820, with the international standard.

ENDRA Life Sciences Inc. (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three months and year ended December 31, 2021 and provided a business update. Highlights of the fourth quarter of 2021 and recent weeks include:

ENDRA Life Sciences Inc. (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the Chinese National Intellectual Property Administration has issued ENDRA two new patents, Chinese Patent No. ZL 2019 8 00400927 (the ‘927 patent) titled “Method and System for Determining Fractional Fat Content of Tissue,” and Chinese Patent No. ZL 2019 8 00870250 (the ‘250 patent) titled “Radio Frequency Applicator and Thermoacoustic Imaging System Employing the Same”.

ENDRA Life Sciences Inc. (ENDRA) (NASDAQNDRA), a pioneer of enhanced ultrasound technologies, today announced that the company will report financial results for the fourth quarter of 2021 on Wednesday, March 30, 2022 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at 4:30 p.m. Eastern time to discuss the results, provide an update on recent corporate developments and answer questions.

ENDRA Life Sciences Inc. (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the European Patent Office (EPO) has issued two new patents to ENDRA, European Patent No. 3668382 (the ‘382 patent) titled “Method and System for Estimating Fractional Fat Content of an Object” and European Patent No. 3661416 (the ‘416 patent) titled “Method for Estimating Fractional Fat Content of an Object.”

ENDRA Life Sciences Inc. (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announced today it will build on the content of its completed 510(k) application and pursue the De Novo pathway for its TAEUS System, which is intended to characterize fatty liver tissue as a means to non-invasively assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD).

ENDRA Life Sciences Inc. (ENDRA) (NASDAQNDRA), a pioneer of enhanced ultrasound technologies, today announced it has received Institutional Review Board approval from China’s renowned Shanghai General Hospital (Shanghai First People’s Hospital Affiliated with Shanghai Jiao Tong University), for the first clinical study of ENDRA’s Thermo Acoustic Enhanced UltraSound (TAEUS®) device to assess Non-Alcoholic Fatty Liver Disease (NAFLD) in that market.

ENDRA Life Sciences Inc. (ENDRA) (NASDAQNDRA), a pioneer of enhanced ultrasound technologies, announces that management will present a company overview at the H.C. Wainwright BioConnect Virtual Conference being held January 10-13, 2022. A webcast of the presentation will be available on-demand beginning January 10, 2022 at 7:00 a.m. Eastern time on the Investors section of ENDRA’s website.

ENDRA Life Sciences Inc. (ENDRA) (NASDAQNDRA), a pioneer of enhanced ultrasound technologies, today announced that King’s College Hospital, London (KCH) is now partnering with ENDRA for a clinical study of ENDRA’s Thermo-Acoustic Enhanced Ultrasound (TAEUS®) device for assessing Non-Alcoholic Fatty Liver Disease (NAFLD).

ENDRA Life Sciences Inc. (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), and VGI Health Technology Limited (NSX: VTL), a clinical-stage biotechnology company specializing in developing and commercializing evidence-based nutraceuticals and pharmaceuticals, announce today the signing of a collaboration agreement to incorporate ENDRA’s proprietary TAEUS technology to support patient screening and biomarker measurement during VGI’s upcoming Phase 2 study of IVB001 in Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH).

ENDRA Life Sciences Inc. (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the United States Patent and Trademark Office has issued two patents, including U.S. Patent No. 11172829 (the ‘829 patent) titled “Thermoacoustic Transducer With Integrated Switch,” and U.S. Patent No. 11176848 (the ‘848 patent) titled “Tissue-mimicking Material for A Multi-modality Imaging Phantom.”

ENDRA Life Sciences Inc. (ENDRA) (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three months ended September 30, 2021 and provided a business update. Highlights of the third quarter of 2021 and recent weeks include:

ENDRA Life Sciences Inc. (ENDRA) (NASDAQNDRA), a pioneer of enhanced ultrasound technologies, today announced that the company will report financial results for the third quarter of 2021 on Monday, November 15, 2021 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at 4:30 p.m. Eastern time to discuss the results, provide an update on recent corporate developments and answer questions.

ENDRA Life Sciences Inc. (NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), has recently been issued U.S. Patent 11147067 (the ‘067 patent) titled, “Method And System For Monitoring Tissue Temperature” from the United States Patent & Trademark Office.